Cargando…

Metabolomics biomarkers to predict acamprosate treatment response in alcohol-dependent subjects

Precision medicine for alcohol use disorder (AUD) allows optimal treatment of the right patient with the right drug at the right time. Here, we generated multivariable models incorporating clinical information and serum metabolite levels to predict acamprosate treatment response. The sample of 120 p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hinton, David J., Vázquez, Marely Santiago, Geske, Jennifer R., Hitschfeld, Mario J., Ho, Ada M. C., Karpyak, Victor M., Biernacka, Joanna M., Choi, Doo-Sup
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451388/ https://www.ncbi.nlm.nih.gov/pubmed/28566752 http://dx.doi.org/10.1038/s41598-017-02442-4

Ejemplares similares

PM307. Untargeted Global Metabolomics Reveals Metabolites Associated with Acamprosate Treatment Outcome
por: Ho, Ada, et al.
Publicado: (2016)

Elevated baseline serum glutamate as a pharmacometabolomic biomarker for acamprosate treatment outcome in alcohol-dependent subjects
por: Nam, H W, et al.
Publicado: (2015)

TSPAN5 influences serotonin and kynurenine: pharmacogenomic mechanisms related to alcohol use disorder and acamprosate treatment response
por: Ho, Ming-Fen, et al.
Publicado: (2020)

Genetic variants associated with acamprosate treatment response in alcohol use disorder patients: A multiple omics study
por: Ho, Ming‐Fen, et al.
Publicado: (2022)

PM321. DNA Methylation Signature Associated with Abstinence in Alcoholics Treated with Acamprosate
por: Hlady, R., et al.
Publicado: (2016)

Genetic markers associated with abstinence length in alcohol-dependent subjects treated with acamprosate
por: Karpyak, V M, et al.
Publicado: (2014)

Plasma TNFSF10 levels associated with acamprosate treatment response in patients with alcohol use disorder
por: Ho, Ming-Fen, et al.
Publicado: (2022)

Safety and Efficacy of Acamprosate for the Treatment of Alcohol Dependence
por: Yahn, Stephanie L., et al.
Publicado: (2013)

Associations of prodynorphin sequence variation with alcohol dependence and related traits are phenotype-specific and sex-dependent
por: Winham, Stacey J., et al.
Publicado: (2015)

Acamprosate: a new tool in the battle against alcohol dependence
por: Wright, Tara M, et al.
Publicado: (2006)

Rare Anaphylactic Reaction to Acamprosate in a Young Alcoholic
por: Patnaik, Asha, et al.
Publicado: (2019)

Acamprosate for treatment of alcohol dependence: mechanisms, efficacy, and clinical utility
por: Witkiewitz, Katie, et al.
Publicado: (2012)

Acamprosate-induced Extrapyramidal Symptoms in an Elderly Patient with Alcohol Dependence
por: Woo, Jungmin, et al.
Publicado: (2014)

Role of acamprosate in sensorineural tinnitus
por: Sharma, Dinesh Kumar, et al.
Publicado: (2012)

Unusual side effects with acamprosate
por: Sidana, Ajeet Kumar, et al.
Publicado: (2007)

Corrigendum to “Genetic predisposition to major depressive disorder differentially impacts alcohol consumption and high-risk drinking situations in men and women with alcohol use disorder” [Drug Alcohol Depend. 243 (2023) 109753]
por: Karpyak, Victor M., et al.
Publicado: (2023)

Calcium acamprosate: a triclinic polymorph
por: Maccaroni, Elisabetta, et al.
Publicado: (2011)

Functional Role of the Polymorphic 647 T/C Variant of ENT1 (SLC29A1) and Its Association with Alcohol Withdrawal Seizures
por: Kim, Jeong-Hyun, et al.
Publicado: (2011)

Replication of Genome Wide Association Studies of Alcohol Dependence: Support for Association with Variation in ADH1C
por: Biernacka, Joanna M., et al.
Publicado: (2013)

Acamprosate in the treatment of alcoholism: a budget impact analysis for the National Health Service in Italy
por: Colombo, Giorgio L, et al.
Publicado: (2012)

PDYN rs2281285 Variant Association with Drinking to Avoid Emotional or Somatic Discomfort
por: Preuss, Ulrich W., et al.
Publicado: (2013)

Deterrent Action of Acamprosate: A Case Report
por: Spoorthy, Mamidipalli Sai, et al.
Publicado: (2019)

Tinnitus treatment with acamprosate: double-blind study
por: Azevedo, Andréia A., et al.
Publicado: (2015)

Sex hormones in alcohol consumption: a systematic review of evidence
por: Erol, Almila, et al.
Publicado: (2017)

Six-Month Outcome in Bipolar Spectrum Alcoholics Treated with Acamprosate after Detoxification: A Retrospective Study
por: Maremmani, Angelo Giovanni Icro, et al.
Publicado: (2014)

A comparative study on the safety and efficacy of naltrexone versus baclofen versus acamprosate in the management of alcohol dependence
por: Kumar, Arun, et al.
Publicado: (2020)

Genetic contributions to alcohol use disorder treatment outcomes: a genome-wide pharmacogenomics study
por: Biernacka, Joanna M., et al.
Publicado: (2021)

Acamprosate-induced myoclonic jerks: A rare side effect
por: Soni, Puneet Kumar, et al.
Publicado: (2021)

Adherence to Prescribed Acamprosate in Alcohol Dependence and 1-Year Morbidities and Mortality: Utilizing a Data Linkage Methodology
por: Tolomeo, Serenella, et al.
Publicado: (2021)

Acamprosate Is a Substrate of the Human Organic Anion Transporter (OAT) 1 without OAT3 Inhibitory Properties: Implications for Renal Acamprosate Secretion and Drug–Drug Interactions
por: Antonescu, Irina E., et al.
Publicado: (2020)

Combination of acamprosate and baclofen as a promising therapeutic approach for Parkinson’s disease
por: Hajj, Rodolphe, et al.
Publicado: (2015)

Sodium acamprosate and calcium exert additive effects on nucleus accumbens dopamine in the rat
por: Ademar, Karin, et al.
Publicado: (2022)

Hypersalivation and coarse tremors as uncommon side effects of acamprosate: A case report
por: Bhandutia, D., et al.
Publicado: (2021)

Gut-brain peptides in corticostriatal-limbic circuitry and alcohol use disorders
por: Vadnie, Chelsea A., et al.
Publicado: (2014)

Genome-wide association study for circulating FGF21 in patients with alcohol use disorder: Molecular links between the SNHG16 locus and catecholamine metabolism
por: Ho, Ming-Fen, et al.
Publicado: (2022)

The rates and measurement of adherence to acamprosate in randomised controlled clinical trials: A systematic review
por: Donoghue, Kim, et al.
Publicado: (2022)

Acamprosate reduces ethanol intake in the rat by a combined action of different drug components
por: Ademar, Karin, et al.
Publicado: (2023)

Acamprosate and Baclofen were Not Effective in the Treatment of Pathological Gambling: Preliminary Blind Rater Comparison Study
por: Dannon, Pinhas N., et al.
Publicado: (2011)

Combination of acamprosate and baclofen (PXT864) as a potential new therapy for amyotrophic lateral sclerosis
por: Boussicault, Lydie, et al.
Publicado: (2020)

Early central Glutamate and GABA changes with Baclofen and Acamprosate among patients with alcohol dependence syndrome: A magnetic resonance spectroscopy based prospective study
por: Khanra, Sourav, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_m1o62m3sg44dkujul1l8lst9pf